|
22 Nov 2025 |
OneSource Specialty Pharma
|
Consensus Share Price Target
|
1630.40 |
2480.25 |
- |
52.13 |
buy
|
|
|
|
|
13 Nov 2025
|
OneSource Specialty Pharma
|
ICICI Securities Limited
|
1630.40
|
2475.00
|
1726.00
(-5.54%)
|
51.80 |
Buy
|
|
|
Delay in generic semaglutide approvals from Canadian regulator may shift the launch timeline by a quarter; however, with a few customers securing the approval in India and approvals in Brazil and Saudi Arabia expected to flow in, OneSource’s management remains confident of the upcoming opportunity, and hence, maintains FY28 guidance for its base business.
|